Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 1,213 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Yvonne Greenstreet also recently made the following trade(s):

• On Tuesday, November 26th, Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62.

Alnylam Pharmaceuticals Trading Down 2.5 %

Shares of Alnylam Pharmaceuticals stock opened at $250.00 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a market cap of $32.25 billion, a PE ratio of -95.42 and a beta of 0.35. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The company has a 50 day simple moving average of $253.96 and a two-hundred day simple moving average of $263.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ALNY shares. Scotiabank decreased their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a report on Friday, February 14th. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Sanford C. Bernstein reduced their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $299.48.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ALNY. Creative Planning lifted its holdings in shares of Alnylam Pharmaceuticals by 24.6% in the 3rd quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock worth $2,754,000 after acquiring an additional 1,978 shares during the last quarter. Bleakley Financial Group LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 24.7% in the 3rd quarter. Bleakley Financial Group LLC now owns 2,215 shares of the biopharmaceutical company’s stock worth $609,000 after acquiring an additional 439 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 431.0% in the 3rd quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 375 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 62.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 161 shares during the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 34.1% in the 3rd quarter. Signaturefd LLC now owns 1,854 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 471 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.